Reporting owner · CIK 0001669976

Brynjelsen Sean

Visual SEC Form 4 history across 1 companies, 11 transactions and 4 filings.

PRES, CEOPresident & CEOEton Pharmaceuticals, Inc.
Open-market mix
Latest filingAug 20, 2026, 10:26 PM
Filings4Form 4 records
Buying$00 purchases
Selling$9.9M6 sales
Net value−$9.9MBuys minus sells
Companies13 securities
Most recentAug 20, 2026sale

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-5Jan 25Jan 262May 264Aug 26

Net value flow

Buys minus sells

Jan 25
$0
Jan 26
$0
May 26
−$3.8M
Aug 26
−$6.1M

Transaction texture

Ownership and ticket size

Average P/S size$1.7M
Median P/S size$1.4M
Direct11
Indirect0
Aug 20, 2026sale

Filing-only signals

Deterministic matches in this insider's history

Cluster Sellingpattern2Delayed Filingfiling-context1Derivative Transactionfiling-context4Direct Ownershipfiling-context11Large Holdings Increaseholdings2Large Salesize3Repeat Sellerpattern4

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Eton Pharmaceuticals, Inc. on Aug 20, 2026 valued at $456,085.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at Eton Pharmaceuticals, Inc. on Aug 20, 2026 valued at $456,085.

Review SEC filing

Associated companies

Visual map of known reporting history

ETONEton Pharmaceuticals, Inc.11 transactions · latest Aug 20, 2026, 10:26 PM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
ETONBRYNJELSEN SEAN
PRESCEO
sale7.34k-$45.6MS
Direct Ownership Repeat Seller
+0.9%08/2008/20
ETONBRYNJELSEN SEAN
PRESCEO
sale36.3k-$222MS
Direct Ownership Large Sale Repeat Seller
+0.9%08/2008/20
ETONBRYNJELSEN SEAN
PRESCEO
sale47.3k-$284MS
Direct Ownership Large Sale Repeat Seller
+0.9%08/2008/20
ETONBRYNJELSEN SEAN
PRESCEO
sale8.97k-$56.2MS
Direct Ownership
+0.9%08/2008/19
ETONBRYNJELSEN SEAN
PRESCEO
sale148-$483kS
Cluster Selling Direct Ownership Repeat Seller
+107.0%05/2905/28
ETONBRYNJELSEN SEAN
PRESCEO
sale119k-$382MS
Cluster Selling Direct Ownership Large Sale
+107.0%05/2905/28
ETONBRYNJELSEN SEAN
PRESCEO
grant100k$0A
Derivative Transaction Direct Ownership
—01/1401/12
ETONBRYNJELSEN SEAN
PRESCEO
grant158k$0A
Derivative Transaction Direct Ownership
—01/1401/12
ETONBRYNJELSEN SEAN
PRESCEO
withholding5.01k-$7.71MF
Delayed Filing Direct Ownership
—01/1401/01
ETONBRYNJELSEN SEAN
PRESCEO
grant72.0k$0A
Derivative Transaction Direct Ownership Large Holdings Increase
—01/06/202501/03/2025

Brynjelsen Sean Insider Activity FAQ

SEC Form 4 context

Who is Brynjelsen Sean?

Brynjelsen Sean is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001669976.

Which companies has Brynjelsen Sean reported transactions for?

Eton Pharmaceuticals, Inc.

When was Brynjelsen Sean's latest insider buy?

No open-market insider purchase is available for this period.

When was Brynjelsen Sean's latest insider sale?

sale at Eton Pharmaceuticals, Inc. on Aug 20, 2026 valued at $456,085.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.